跳至主要内容
临床试验/NCT05887791
NCT05887791已完成不适用

Clinical Study to Assess the Effect of a Collagen Hydrolysate on Postprandial Blood Glucose Profile in Prediabetic and Healthy Subjects: Randomized, Double-blind, Placebo-controlled, Cross-over Study With Different Dosages

Rousselot BVBA2 个研究点 分布在 1 个国家目标入组 16 人开始时间: 2023年6月15日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
16
试验地点
2
主要终点
Glucose iAUC

研究概览

简要总结

To investigate the effect of two different dosages collagen hydrolysate (CH) on postprandial blood glucose and insulin profile in prediabetic and normo-glycaemic subjects.This will be investigated in a cross-over randomized double-blind placebo controlled study design.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Prevention
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Main Inclusion Criteria:
  • Prediabetic subjects: Male and female subjects with prediabetic HbA1c values between 5.7% and 6.4% and/or fasting glucose ≥ 100 mg/dL and ≤ 125 mg/dL (in venous plasma) (twice confirmed at two independent days if HbA1c is < 5.7%) or Healthy normo-glycaemic subjects: fasting glucose <100 mg/dL and HbA1c is < 5.7%
  • Age: 18-70 years
  • Body mass index 19-35 kg/m2
  • Current Non-smoker
  • Signed informed consent form
  • No changes in food habits or physical activity 3 months prior to screening and during the study
  • If applicable, stable intake of chronic medication of at least 4 weeks

排除标准

  • Subjects with diagnosed Type 2 Diabetes mellitus with medical treatment
  • Presence of disease or drug(s) influencing digestion (incl. recent intake of antibiotics) and absorption of nutrients
  • Intake of medications known to affect glucose tolerance, e.g., diabetic medication, SGLT-2 inhibitors, GLP-1 receptor agonists, steroids, protease inhibitors or antipsychotics
  • Chronic intake of substances affecting blood coagulation (e.g. acetylic acid (100 mg as standard prophylactic treatment allowed when dose is stable 1 month prior to screening), anticoagulants, diuretics, thiazides (diuretics and thiazides allowed e.g. for hypertension treatment when dose is stable 1 month prior to screening)), which in the Investigator's opinion would impact patient safety
  • Severe liver or renal disease or laboratory evidence of hepatic dysfunction (i.e. alkaline phosphatase, ALT, AST >3 x ULN)
  • Known inflammatory or malignant gastrointestinal diseases (i.e. colitis ulcerosa, Morbus Crohn, celiac disease, malignant diseases e.g. colon-cancer, rectum cancer, pancreatitis)
  • Clinically relevant findings as established by medical history, physical examination, clinical laboratory and/or vital signs
  • Intake of food supplements known to affect glucose tolerance, e.g., cinnamon capsules, conjugated linoleic acids
  • Drug-, alcohol- and medication abuses
  • Pregnant or breast-feeding women

研究组 & 干预措施

Placebo

Placebo Comparator

Flavoured water

干预措施: Placebo (Other)

Collagen hydrolysate dose 1

Experimental

Source: porcine; standardized to 10 g provided as single dose. Orally applied in flavoured water.

干预措施: Collagen hydrolysate (Dietary Supplement)

Collagen hydrolysate dose 2

Experimental

Source: porcine; standardized to 5 g provided as single dose. Orally applied in flavoured water.

干预措施: Collagen hydrolysate (Dietary Supplement)

结局指标

主要结局

Glucose iAUC

时间窗: 0-180 minutes postprandially

Area under the curve (AUC) calculated as the incremental area under the blood glucose response curve, ignoring the area beneath the fasting concentration: Glucose-iAUC(0-180minutes)

次要结局

  • Satiety assessment(0-240 minutes postprandially)
  • Glucose Cmax(0-180 minutes postprandially)
  • Tmax(0-180 minutes postprandially)
  • Delta Cmax(0-180 minutes postprandially)
  • T baseline(0-240 minutes postprandially)
  • Insulin iAUC(up to 0-240 minutes postprandially)
  • GLP-1(0-120 minutes postprandially)
  • Glucose iAUC(0-240 minutes postprandially)
  • Matsuda-Index(0-120 minutes postprandially)
  • Glucose dip(0-240 minutes postprandially)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验